TriSalus Life Sciences (TLSI) Set to Announce Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) will be posting its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect TriSalus Life Sciences to post earnings of ($0.37) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The firm had revenue of $7.36 million during the quarter. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $4.16 on Thursday. The company has a fifty day moving average price of $4.46 and a 200-day moving average price of $6.05. The firm has a market cap of $121.93 million, a price-to-earnings ratio of -1.66 and a beta of 0.49. TriSalus Life Sciences has a 1 year low of $3.32 and a 1 year high of $10.42.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 7,520 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 32.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on TLSI shares. Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences presently has an average rating of “Buy” and a consensus price target of $12.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.